Clinical Characteristics and Molecular Analysis of PIT1, PROP1,LHX3, and HESX1 in Combined Pituitary Hormone Deficiency Patients with Abnormal Pituitary MR ImagingKim S.-S.a · Kim Y.a · Shin Y.-L.a · Kim G.-H.a · Kim T.-U.b · Yoo H.-W.a
aDepartment of Pediatrics, Asan Institute for Life Sciences, Asan Medical Center, University of Ulsan College of Medicine, Seoul, and bDepartment of Biomedical Laboratory Science, College of Health Science, Tonsei University, Wonju, Korea
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Article / Publication Details
Background/Aims: Many genes encoding pituitary transcription factors involved in the formation of the pituitary gland are identified. Different mutations in these genes have been reported in patients with familial combined pituitary hormone deficiency (CPHD). This study was undertaken to analyze PIT1, PROP1, LHX3, and HESX1 in 12 CPHD patients with abnormal pituitary magnetic resonance imaging (MRI). Since embryonic development of the pituitary requires the coordinated expression of specific transcription factors, we postulated the presence of mutations in PIT1, PROP1, LHX3, and HESX1 genes. Methods: Anterior pituitary function was evaluated. Each gene was PCR amplified exon by exon, and subsequently sequenced. Results: In all cases, MRI examination showed abnormal pituitary gland development featuring ectopic neurohypophysis, hypoplastic anterior lobe, empty sella, and septo-optic dysplasia. Endocrinologically, all patients revealed multiple pituitary hormone deficiency including growth hormone, thyroid stimulating hormone, luteinizing hormone, follicular stimulating hormone and adrenocorticotropin. They were all sporadic cases without a positive family history. None of disease-causing specific mutations were identified in PIT1, PROP1, LHX3, and HESX1 genes of 12 sporadic CPHD patients with abnormal pituitary imaging. However, 2 novel polymorphisms were found in PROP1 gene: IVS1+3 A→G and 27 T→C (Ala9Ala) in exon 1. Their allele frequencies in patients and normal controls were not statistically different. Overall, allele frequencies of these polymorphisms were as follows: for the IVS1+3 A→G polymorphism, the allele frequency of A was 54%, and 46% for G, with 58% of an A/G heterozygosity. For the 27 T→C (Ala9Ala) polymorphism, the allele frequency of T was 46%, and 54% for G, with 42% of a T/C heterozygosity. Conclusions: Mutations of PIT1, PROP1, LHX3, and HESX1 genes are very rare in sporadic CPHD patients with abnormal pituitary MRI.
© 2003 S. Karger AG, Basel
- Abrahams JJ, Trefelner E, Boulware SD: Idiopathic growth hormone deficiency: MR findings in 35 patients. Am J Neuroradiol 1991;12:155–160.
- Cacciari E, Zucchini S, Carla G, Pirazzoli P, Cicognai A, Mandini M, Busacca M, Trevisan C: Endocrine function and morphological findings in patients with disorders of the hypothalamo-pituitary area: A study with magnetic resonance. Arch Dis Child 1990;65:1199–1202.
- Maghnie M, Triulzi F, Larizza D, Preti P, Priora C, Scotti G, Severi F: Hypothalamic-pituitary dysfunction in growth hormone deficient patients with pituitary abnormalities. J Clin Endocrinol Metab 1991;73:79–83.
Fujisawa I, Kikuchi K, Nishimura K, Togashi K, Itoh K, Noma S, Minami S, Sagoh T, Hiraoka T, Monomi T, Mikawa K, Nakamo Y, Itoh H, Komishi J: Transection of the pituitary stalk: Development of an ectopic posterior lobe assessed with MR imaging. Radiology 1987;165:486–489.
- Kuroiwa T, Okabe Y, Hasuo K, Yasumori K, Mizushima A, Masuda K: MR imaging of pituitary dwarfism. Am J Neuroradiol 1991;12:161–164.
- Lopez-Bermejo A, Buckway CK, Rosenfeld RG: Genetic defects of the growth hormone-insulin-like growth factor axis. Trends Endocrinol Metab 2000;11:39–49.
- Mullis PE: Transcription factors in pituitary gland development and their clinical impact on phenotype. Horm Res 2000;54:107–119.
- Deladoey J, Fluck C, Buyukgebiz A, Kuhlmann BV, Eble A, Hindmarsh PC, Wu W, Mullis PE: ‘Hot spot’ in the PROP1 gene responsible for combined pituitary hormone deficiency. J Clin Endocrinol Metab 1999;84:1645–1650.
- Netchine I, Sobrier M-L, Krude H, Schnabel D, Maghnie M, Marcos E, Duriez B, Cacheux V, Moer AV, Gossens M, Gruters A, Amselem S: Mutations in LHX3 result in a new syndrome revealed by combined pituitary hormone deficiency. Nat Genet 2000;25:182–186.
- Dattani MT, Martinez-Barbera J-P, Thomas PQ, Brickman JM, Gupta R, Martensson I-L, Toresson H, Fox M, Wales JKH, Hindmarsh PC, Krauss S, Beddington RSP, Robinson ICAF: Mutations in the homeobox gene HESX1/Hesx1 associated with septo-optic dysplasia in human and mouse. Nat Genet 1998:19:125–133.
- Ohta K, Nobukuni Y, Mitsubuchi H, Fujimoto S, Matsuo N, Inagaki H, Endo F, Matsuda I: Mutations in the Pit-1 gene in children with combined pituitary hormone deficiency. Biochem Biophys Res Commun 1992;189:851–855.
- Sloop KW, Walvoord EC, Showalter AD, Pescovitz OH, Rhodes SJ: Molecular analysis of LHX3 and Prop-1 in pituitary hormone deficiency patients with posterior pituitary ectopia. J Clin Endocrinol Metab 2000;85:2701–2708.
- Argyropoulou A, Perignon F, Brauner R, Brunelle F: Magnetic resonance imaging in the diagnosis of growth hormone deficiency. J Pediatr 1992;120:886–891.
- Kelly WM, Kucharczyk W, Kucharczyk J: Posterior pituitary ectopia: An MR features of pituitary dwarfism. Am J Neuroradiol 1988;9:453–460.
- Chen S, Léger J, Garel C, Hassan M, Czernichow PJ: Growth hormone deficiency with ectopic neurohypophysis: Anatomic variations and relationship between the visibility of the pituitary stalk asserted by magnetic resonance imaging and anterior pituitary function. J Clin Endocrinol Metab 1999;84:2408–2413.
Margalith D, Tze WJ, Jan JE: Congenital optic nerve hypoplasia with hypothalamic-pituitary dysplasia. A review of 16 cases. Am J Dis Child 1985;139:361–366.
Cushman LJ, Showalter AD, Rhodes SJ: Genetic defects in the development and function of the anterior pituitary gland. Ann Med 2002;34:179–191.
- Aarskog D, Eiken HG, Bjerknes R, Myking OL: Pituitary dwarfism in the R271W Pit-1 gene mutation. Euro J Pediatr 1997;156:829–834.
- Fofanova O, Takamura N, Kinoshita E, Parks JS, Brown MR, Peterkova VA, Evgrafov OV, Goncharov NP, Bulatov AA, Dedov II, Yamashita S: Compound heterozygous deletion of the PROP-1 gene in children with combined pituitary hormone deficiency. J Clin Endocrinol Metab 1998;83:2601–2604.
- Cogan JD, Wu W, Phillips JA, Arnhold IJP, Agapito A, Fofanova OV, Osorio MGF, Bircan I, Moreno A, Mendonca BB: The PROP1 2-base pair deletion is a common cause of combined pituitary hormone deficiency. J Clin Endocrinol Metab 1998;83:3346–3349.
- Mody S, Brown MR, Parks JS: The spectrum of hypopituitarysm caused by PROP1 mutations. Best Pract Res Clin Endocrinol Metab 2002;16:421–431.
Turton JPG, McNay D, Cassar J, Bouloux PM, Attard-Montalto S, Pakov AT, Hindmarsh PC, Dattani MT: Mutations within PROP1 and PIT1 are rare causes of combined pituitary hormone deficiency (CPHD). Pediatr Res 2001;49:34A.
- Sheng HZ, Zhadanov AB, Mosinger B, Fujii T, Bertuzzi S, Grinberg A, Lee EJ, Huang SP, Mahon KA, Westphal H: Specification of pituitary cell lineages by the LIM homeobox gene Lhx3. Science 1996;272:1004–1007.
Thomas PQ, Datani MT, Cooke S, Martinez-Barbera, Brickman J, Warne G, Zacharin M, Cameron, Agarwal G, Bhatia V, Robinson M, Beddington RSP: Pituitary development and disease: The role of homeobox genes. J Pediatr Endocrinol Metab 2000;13:1173.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.